Hyperthyroidism Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Sep 29, 2011, 05:58 ET from Reportlinker

NEW YORK, Sept. 29, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Hyperthyroidism Therapeutics - Pipeline Assessment and Market Forecasts to 2017

http://www.reportlinker.com/p0648869/Hyperthyroidism-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Hyperthyroidism Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, "Hyperthyroidism Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Hyperthyroidism market. The report identifies the key trends shaping and driving the global Hyperthyroidism market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Hyperthyroidism sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

The global Hyperthyroidism therapeutics market was valued at $375m in 2010 and is forecast to grow at a compound annual growth rate (CAGR) of 2.9% to reach $459m in 2017. The growth of the market will be slow due to the dominance of generics and the lack of approved drugs. The primary factor driving the market is the increase in the elderly population. At present, the market is served by therapies such as antithyroid agents (methimazole, propylthiouracil, carbimazole), radioactive iodine and beta blockers used as an adjuvant therapy. The market is dominated by generics. As the disease is curable if identified in time, the unmet need is low. Despite the efficient therapies available for the indication, there are still some unmet needs that can be tapped by products with better efficacy and safety.

Scope

The report provides information on the key drivers and challenges of the Hyperthyroidism market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Hyperthyroidism market revenues data from 2005 to 2010, forecast for seven years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as anti-CD3, anti-CD20 and TSH mimicking.

- Analysis of the current and future competition in the seven key countries Hyperthyroidism market. Key market players covered are Genzyme (acquired by Sanofi) and GlaxoSmithKline.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Hyperthyroidism therapeutics market.

- Analysis of key recent licensing and partnership agreements in Hyperthyroidism market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Hyperthyroidism market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Hyperthyroidism market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Hyperthyroidism market landscape? – Identify, understand and capitalize.

1 Table of contents

1 Table of contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 Hyperthyroidism Therapeutics - Introduction 6

2.1 Overview 6

2.2 Epidemiology 6

2.3 Etiology 7

2.4 Signs and Symptoms 8

2.5 Diagnosis 9

2.6 Pathophysiology 11

2.7 Treatment and Management Pattern 12

2.8 GlobalData Pipeline Report Guidance 15

3 Hyperthyroidism Therapeutics - Market Characterization 16

3.1 Hyperthyroidism Therapeutics Market Size (2005-2010) - Global 16

3.2 Hyperthyroidism Therapeutics Market Forecast (2010-2017) - Global 17

3.3 Hyperthyroidism Therapeutics Market Size (2005-2010) - The US 18

3.4 Hyperthyroidism Therapeutics Market Forecast (2010-2017) - The US 19

3.5 Hyperthyroidism Therapeutics Market Size (2005-2010) - France 20

3.6 Hyperthyroidism Therapeutics Market Forecast (2010-2017) - France 21

3.7 Hyperthyroidism Therapeutics Market Size (2005-2010) - Germany 22

3.8 Hyperthyroidism Therapeutics Market Forecast (2010-2017) - Germany 23

3.9 Hyperthyroidism Therapeutics Market Size (2005-2010) - Spain 24

3.10 Hyperthyroidism Therapeutics Market Forecast (2010-2017) - Spain 25

3.11 Hyperthyroidism Therapeutics Market Size (2005-2010) - Italy 26

3.12 Hyperthyroidism Therapeutics Market Forecast (2010-2017) - Italy 27

3.13 Hyperthyroidism Therapeutics Market Size (2005-2010) - The UK 28

3.14 Hyperthyroidism Therapeutics Market Forecast (2010-2017) - The UK 29

3.15 Hyperthyroidism Therapeutics Market (2005-2010) - Japan 30

3.16 Hyperthyroidism Therapeutics Market Forecast (2010-2017) - Japan 31

3.17 Drivers and Barriers for the Hyperthyroidism Therapeutics Market 32

3.17.1 Hyperthyroidism Therapeutics Market Drivers 32

3.17.2 Hyperthyroidism Therapeutics Market Restraints 32

3.18 Opportunities and Unmet Needs 33

3.19 Key Takeaway 33

4 Hyperthyroidism Therapeutics - Competitive Assessment 34

4.1 Overview 34

4.2 Strategic Competitor Assessment 34

4.3 Product Profile for the Major Market Products in the Hyperthyroidism Therapeutics Market 35

4.3.1 Antithyroid drugs 35

4.3.2 Radioactive Iodine Therapy 35

4.3.3 Beta blockers 35

4.4 Key Takeaway 35

5 Hyperthyroidism Therapeutics - Pipeline Assessment 36

5.1 Overview 36

5.2 Strategic Pipeline Assessment 36

5.3 Hyperthyroidism Therapeutics Market - Pipeline Assessment by Phase of Development 36

5.3.1 Hyperthyroidism Therapeutics Market - Phase II Pipeline 36

5.3.2 Hyperthyroidism Therapeutics Market - Phase I Clinical Pipeline 36

5.4 Hyperthyroidism Therapeutics - Pipeline by Mechanism of Action 37

5.5 Technology Trends Analytical Framework 38

5.6 Key Takeaway 38

6 Hyperthyroidism Therapeutics - Clinical Trials Mapping 39

6.1 Clinical Trials by Region/Country (the US, EU5 and Japan) 39

6.2 Clinical Trials by Trial Status 40

6.3 Prominent Sponsors 41

7 Hyperthyroidism Therapeutics - Strategic Assessment 42

7.1 Key Events Impacting the Future Market 42

7.2 Future Market Competition Scenario 42

8 Hyperthyroidism Therapeutics - Future Players 44

8.1 Introduction 44

8.2 Company Profiles 44

8.2.1 Genzyme Corporation 44

8.2.2 GlaxoSmithKline Plc. 45

8.2.3 Key Takeaway 46

9 Hyperthyroidism Therapeutics - Licensing & Partnership Deals 47

10 Hyperthyroidism Therapeutics - Appendix 48

10.1 Market Definitions 48

10.2 Abbreviations 48

10.3 Methodology 48

10.3.1 Coverage 49

10.3.2 Secondary Research 49

10.3.3 Primary Research 52

10.4 Expert Panel Validation 52

10.5 Contact Us 52

10.6 Disclaimer 52

10.7 Bibliography 53

List of Tables

Table 1: Hyperthyroidism Therapeutics - Epidemiology 7

Table 2: Hyperthyroidism Therapeutics - Common Etiology and Clinical Diagnosis 8

Table 3: Hyperthyroidism Therapeutics - Treatment Options 13

Table 4: Hyperthyroidism Therapeutics Market, Global, Revenue ($m), 2005 - 2010 16

Table 5: Hyperthyroidism Therapeutics Market, Global, Forecast ($m), 2010 - 2017 17

Table 6: Hyperthyroidism Therapeutics Market, The US, Revenue ($m), 2005 - 2010 18

Table 7: Hyperthyroidism Therapeutics Market, The US, Forecast ($m), 2010 - 2017 19

Table 8: Hyperthyroidism Therapeutics, France, Revenue ($m), 2005 - 2010 20

Table 9: Hyperthyroidism Therapeutics Market, France, Forecasts ($m), 2010 - 2017 21

Table 10: Hyperthyroidism Therapeutics, Germany, Revenue ($m), 2005 - 2010 22

Table 11: Hyperthyroidism Therapeutics Market, Germany, Forecast ($m), 2010 - 2017 23

Table 12: Hyperthyroidism Therapeutics, Spain, Revenue ($m), 2005 - 2010 24

Table 13: Hyperthyroidism Therapeutics Market, Spain , Forecast ($m), 2010 - 2017 25

Table 14: Hyperthyroidism Therapeutics, Italy , Revenue ($m), 2005 - 2010 26

Table 15: Hyperthyroidism Therapeutics Market, Italy, Forecast ($m), 2010 - 2017 27

Table 16: Hyperthyroidism Therapeutics, The UK, Revenue ($m), 2005 - 2010 28

Table 17: Hyperthyroidism Therapeutics Market, The UK, Forecast ($m), 2010 - 2017 29

Table 18: Hyperthyroidism Therapeutics, Japan, Revenue ($m), 2005 - 2010 30

Table 19: Hyperthyroidism Therapeutics Market, Japan, Forecasts ($m), 2010 - 2017 31

Table 20: Hyperthyroidism Therapeutics - Phase II Pipeline, 2010 36

Table 21: Hyperthyroidism Therapeutics - Phase I Pipeline, 2010 36

Table 22: Hyperthyroidism Therapeutics - Clinical Trials by Country, 2010 39

Table 23: Hyperthyroidism Therapeutics, Major Markets, Clinical Trials by Development Status, 2010 40

Table 24: Hyperthyroidism Therapeutics, Major Markets, Prominent Sponsors, 2010 41

Table 25: Genzyme Pipeline Products 45

Table 26: GlaxoSmithKline Pipeline Products 46

Table 27: Hyperthyroidism Therapeutics - Licensing Agreement 47

List of Figures

Figure 1: Hyperthyroidism Therapeutics - State of Thyroid Gland 6

Figure 2: Hyperthyroidism Therapeutics - Signs and Symptoms 9

Figure 3: Hyperthyroidism Therapeutics - Diagnosis Pattern 10

Figure 4: Hyperthyroidism Therapeutics - Pathophysiology 11

Figure 5: Hyperthyroidism Therapeutics - Treatment pattern 14

Figure 6: Hyperthyroidism Therapeutics Market, Global, Revenue ($m), 2005 - 2010 16

Figure 7: Hyperthyroidism Therapeutics Market, Global, Forecast ($m), 2010 - 2017 17

Figure 8: Hyperthyroidism Therapeutics Market, The US, Revenue ($m), 2005 - 2010 18

Figure 9: Hyperthyroidism Therapeutics Market, The US, Forecast ($m), 2010 - 2017 19

Figure 10: Hyperthyroidism Therapeutics Market, France, Revenue ($m), 2005 - 2010 20

Figure 11: Hyperthyroidism Therapeutics Market, France, Forecast ($m), 2010 - 2017 21

Figure 12: Hyperthyroidism Therapeutics Market, Germany, Revenue ($m), 2005 - 2010 22

Figure 13: Hyperthyroidism Therapeutics Market, Germany, Forecast ($m), 2010 - 2017 23

Figure 14: Hyperthyroidism Therapeutics Market, Spain, Revenue ($m), 2005 - 2010 24

Figure 15: Hyperthyroidism Therapeutics Market, Spain, Forecast ($m), 2010 - 2017 25

Figure 16: Hyperthyroidism Therapeutics Market, Italy, Revenue ($m), 2005 - 2010 26

Figure 17: Hyperthyroidism Therapeutics Market, Italy, Forecast ($m), 2010 - 2017 27

Figure 18: Hyperthyroidism Therapeutics Market, The UK, Revenue ($m), 2005 - 2010 28

Figure 19: Hyperthyroidism Therapeutics Market, The UK, Forecast ($m), 2010 - 2017 29

Figure 20: Hyperthyroidism Therapeutics Market, Japan, Revenue ($m), 2005 - 2010 30

Figure 21: Hyperthyroidism Therapeutics Market, Japan, Forecast ($m), 2010 - 2017 31

Figure 22: Opportunity and Unmet Need in the Hyperthyroidism Therapeutics Market 33

Figure 23: Strategic Competitor Assessment, 2010 34

Figure 24: Hyperthyroidism Therapeutics - Clinical Pipeline by Mechanism of Action, 2010 37

Figure 25: Hyperthyroidism Therapeutics Market - Pipeline by Phase of Development, 2010 37

Figure 26: Technology Trends Analytics Framework, 2010 38

Figure 27: Technology Trends Analytics Framework - Description, 2010 38

Figure 28: Hyperthyroidism Therapeutics - Clinical Trials by Country, 2010 39

Figure 29: Hyperthyroidism Therapeutics, Major Markets, Clinical Trials by Development Status, 2010 40

Figure 30: Hyperthyroidism Therapeutics, Major Markets, Overall Sponsors, 2010 41

Figure 31: Hyperthyroidism Therapeutics, Major Markets, Overall Sponsors, 2010 41

Figure 32: Hyperthyroidism Therapeutics Market, Drivers and Restraints 2010 42

Figure 33: Implications for Future Market Competition in the Hyperthyroidism Therapeutics Market, 2010 42

Figure 34: Hyperthyroidism Therapeutics Market - Clinical Pipeline by Company, 2010 44

Figure 35: GlobalData Market Forecasting Model 51

Companies Mentioned

Genzyme Corporation

GlaxoSmithKline Plc.

To order this report:

Pathology Industry: Hyperthyroidism Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Pathology Business News

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com